JP2009504654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504654A5 JP2009504654A5 JP2008526124A JP2008526124A JP2009504654A5 JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5 JP 2008526124 A JP2008526124 A JP 2008526124A JP 2008526124 A JP2008526124 A JP 2008526124A JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- yellow fever
- chimeric flavivirus
- fever virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70703805P | 2005-08-10 | 2005-08-10 | |
| US60/707,038 | 2005-08-10 | ||
| US71944805P | 2005-09-22 | 2005-09-22 | |
| US60/719,448 | 2005-09-22 | ||
| PCT/US2006/030846 WO2007021672A2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504654A JP2009504654A (ja) | 2009-02-05 |
| JP2009504654A5 true JP2009504654A5 (enExample) | 2010-08-19 |
| JP5227172B2 JP5227172B2 (ja) | 2013-07-03 |
Family
ID=37758084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526124A Expired - Fee Related JP5227172B2 (ja) | 2005-08-10 | 2006-08-09 | デングウイルス感染に対するワクチン接種 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080193477A1 (enExample) |
| EP (1) | EP1924280A4 (enExample) |
| JP (1) | JP5227172B2 (enExample) |
| AR (1) | AR055603A1 (enExample) |
| AU (1) | AU2006280144B2 (enExample) |
| BR (1) | BRPI0614265A2 (enExample) |
| CA (1) | CA2618783A1 (enExample) |
| IL (1) | IL189329A (enExample) |
| MY (1) | MY151051A (enExample) |
| NO (1) | NO20081127L (enExample) |
| TW (1) | TW200740458A (enExample) |
| WO (1) | WO2007021672A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| CN102449172A (zh) * | 2009-06-01 | 2012-05-09 | 伊维拉根公司 | 施用针对登革病毒的疫苗的组合物和方法 |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| EP2834265A4 (en) | 2012-04-02 | 2015-10-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES |
| US20150265695A1 (en) | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| KR20150036592A (ko) | 2012-07-24 | 2015-04-07 | 사노피 파스퇴르 | 백신 조성물 |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| EP2931310A4 (en) | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
| CA3177574C (en) * | 2013-03-15 | 2026-03-31 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for dengue virus chimeric constructs in vaccines |
| AU2015217149B2 (en) * | 2014-02-11 | 2020-09-10 | Massachusetts Institute Of Technology | Novel full spectrum anti-dengue antibody |
| ES2927797T3 (es) | 2014-09-26 | 2022-11-11 | Seqirus Uk Ltd | Vacunación de sujetos inmunocomprometidos |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| WO2018183426A1 (en) * | 2017-03-30 | 2018-10-04 | Merck Sharp & Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
| JP7313345B2 (ja) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | デング熱に対するブースターワクチン接種のための組成物 |
| US11590221B2 (en) | 2018-09-05 | 2023-02-28 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| WO2021034349A1 (en) | 2019-08-16 | 2021-02-25 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis a |
| US20240076631A2 (en) | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| CN120225693A (zh) | 2022-11-18 | 2025-06-27 | 武田疫苗股份有限公司 | 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法 |
| EP4626574A1 (en) | 2022-11-29 | 2025-10-08 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7192593B2 (en) * | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en not_active Ceased
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/ja not_active Expired - Fee Related
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/pt not_active Application Discontinuation
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-10 AR ARP060103502A patent/AR055603A1/es unknown
- 2006-08-10 TW TW095129386A patent/TW200740458A/zh unknown
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martinez-Flores et al. | SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants | |
| Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
| JP6830118B2 (ja) | ワクチン組成物 | |
| JP5227172B2 (ja) | デングウイルス感染に対するワクチン接種 | |
| JP2013542224A5 (enExample) | ||
| ES2337893T3 (es) | Vacuna del virus del nilo occidental. | |
| JP6943908B2 (ja) | 迅速かつ持続的な免疫学的治療法 | |
| JP2008529558A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| ATE526411T1 (de) | Avirulente, immunogene flavivirus-chimäre | |
| AU2017297608A1 (en) | Compositions and methods for flavivirus vaccination | |
| Zingaretti et al. | Why is it so difficult to develop a hepatitis C virus preventive vaccine? | |
| CN116348101A (zh) | 嵌合腺病毒载体 | |
| AU2022205163B2 (en) | Hepatitis B immunisation regimen and compositions | |
| JP2023518340A5 (enExample) | ||
| Takei et al. | Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice | |
| JP2010506926A5 (enExample) | ||
| Chen et al. | Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses | |
| Valiakos et al. | West Nile virus: Basic principles, replication mechanism, immune response and important genetic determinants of virulence | |
| Kieny et al. | Research and development of new vaccines against infectious diseases | |
| ES2644801T3 (es) | Antígenos de vacuna quimérica contra el virus de la hepatitis c | |
| ES2637629T3 (es) | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo | |
| Sanicas et al. | A review of COVID-19 vaccines in development: 6 months into the pandemic | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| US10160979B2 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis C |